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Abstract
Background: The use of the EQ-5D to asses the economic benefits of health technologies has led to questions
about the cross-population transferability of preference weights to calculate health utility scores. The aim of this
study is to investigate whether the use of UK and Canadian preference weights will lead to the calculation of
different health utility scores in a sample of persons with Alzheimer’s disease (AD) and their primary informal
caregivers.
Methods: We recruited 216 patient-caregiver dyads from nine geriatric and memory clinics across Canada.
Participants used the EQ-5D-3L to rate their health-related quality-of-life (HRQoL). EQ-5D-3L responses were
transformed into health utility scores using UK and Canadian preference weights. The levels of agreement between
the two sets of scores were assessed using intraclass correlation coefficients (ICCs). Bland-Altman plots depicted
individual-level differences between the two sets of scores. Differences in health utility scores were tested using the
Wilcoxon signed rank sum test. A generalized linear model with a gamma distribution was used to examine
whether participants’ socio-demographic characteristics were associated with their health utility scores.
Results: The distributions of health utility scores derived from both the UK and Canadian preference weights were
skewed to the left. The intraclass correlation coefficient was 0.94 (95 % CI: 0.92, 0.95) for persons with AD and 0.92
(95 % CI: 0.88, 0.94) for the caregivers. The Canadian weights yielded slightly higher median health utility scores
than the UK weights for caregivers (median difference: 0.009; 95 % confidence interval: 0.007, 0.013). This finding
persisted after stratifying by disease severity. Few socio-demographic characteristics were associated with the two
sets of health utility scores.
Conclusions: Health utility scores exhibited small and clinically unimportant differences when calculated with UK
versus Canadian preference weights in persons with AD and their caregivers. The original UK and Canadian
population samples used to obtain the preference weights valued health states similarly.
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Background
Alzheimer’s disease (AD) is a chronic neurodegerative
condition that accounts for 60 to 70 % of all cases of
dementia. Cognitive impairment, functional decline, and
behavior and mood problems are the core features of
AD [1]. AD and other dementias are the seventh leading
cause of mortality and disability and the fourth leading
cause of disease burden in high-income countries [2].
Health-related quality of life (HRQoL) is an individ-
ual’s dynamic perception of the impact of a health state
upon physical, emotional, and cognitive function, social
role performance, well-being, and life satisfaction [3].
HRQoL is an important means of assessing the impact
of AD treatments because available therapies mitigate
the symptoms of cognitive decline, but do not alter the
progression of the disease [4].
The EQ-5D-3L is one of the most frequently used gen-
eric instruments to measure HRQoL [5–7]. Algorithms
(preference weights) can be used to convert EQ-5D-3L
responses into health utility scores (range: 0 [equivalent
to death] to 1 [equivalent to full health]), which are
employed in cost-utility analyses to calculate quality-
adjusted life-years (QALYs). The original preference
weights for the EQ-5D-3L were derived from the general
UK population using the time trade-off (TTO) method
[8]. Researchers generated a Canadian set of preference
weights for the EQ-5D-3L using the TTO method and a
sample of 1145 participants who belonged to a market
research panel [9]. In the UK and Canadian studies, the
researchers chose different sub-sets of health states from
the 243 total possible health states on the EQ-5D-3L.
These sub-sets were further divided into smaller groups
for each participant to value using the TTO method.
Regression analyses were employed to develop a set of
beta coefficients that would serve as the preference
weights to convert EQ-5D-3L responses into health
utility scores.
This study investigated whether the use of UK and
Canadian preference weights would lead to the compu-
tation of different health utility scores in a sample of
persons with AD and their primary informal caregivers.
The topic is important because studies based in popula-
tions without domestic sets of preference weights will often
draw upon the preference weights of other populations,
regardless of whether the other populations’ weights are
transferable. Unless transferability is assessed, researchers
cannot be certain whether another population’s weights
will provide unbiased health utility scores in their popula-
tion of interest.
This issue is important within the context of AD because
health utility scores are essential components of cost-utility
analyses. These analyses can influence reimbursement
decisions for AD pharmacotherapies, as evidenced in 2006
when the results of a cost-utility analysis prompted the
United Kingdom’s National Health Service to delist cover-
age of cholinetserase inhibitors for persons with mild AD.
The impact of cost-utility analyses on treatment decision-
making highlights the importance of ensuring the unbiased
nature of the underlying health utility scores.
Recent work in Canada has echoed our sentiments about
the use of adequate preference weights in cost-utility
analyses [10]. Lien et al. point out that differences in
country-specific preference weights could lead to differ-
ences in cost-utility results [10]. Similar concerns have also
been raised in Italy [11]. In the context of Canada’s
publicly-funded healthcare system, decisions regarding the
efficient allocation of limited resources require support
from unbiased analyses of cost-utility data. The issue
extends beyond Canada to include any jurisidiction with-
out a locally or domestically available set of preference
weights. An examination of this issue may raise awareness
among regulatory agencies that do not mandate the use of
local or domestic preference weights.
To round out our objectives, we also explored whether
socio-demographic factors might be associated with the
health utility scores calculated in this study.
Methods
Subjects and data collection
Data were collected between November 2008 and
August 2011 [12]. Two hundred sixteen persons with
AD and their primary informal caregivers were recruited
from nine memory or geriatric clinics across Canada.
Eligible participants had a diagnosis of AD, as defined by
the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text revision criteria [13] or the National
Institute of Neurological and Communicative Disorders
and Stroke/Alzheimer’s Disease and Related Disorders
Association criteria (NINCDS-ADRDA) [14]. We included
persons with mild or moderate AD to ensure that partici-
pants would be cognitively capable of answering the study
questions. The physicians who ran the recruiting clinics
assessed disease severity using the Functional Assessment
Staging in Alzheimer’s Disease Scale [15]. Participants’
primary informal caregivers also had to agree to par-
ticipate in the study. All participants had to speak
English or French.
We conducted separate one-on-one interviews with each
participant. The interviews included socio-demographic
questions (i.e., age, gender, education level, occupation and
household annual income [Canadian dollars]) and the EQ-
5D-3L. Each participant rated her or his own HRQoL.
Caregivers did not provide proxy HRQoL ratings for
persons with AD.
Prior to commencing each interview, participants read
an information package about the study and they could ask
the interviewer questions. The interviews began after par-
ticipants signed an informed consent form. The study
Fang et al. Health and Quality of Life Outcomes  (2016) 14:105 Page 2 of 8
received ethics approval from the Hamilton Health
Sciences/McMaster Health Sciences Research Ethics Board
(project number 08-179) and from the local research ethics
boards governing each of the nine recruitment sites.
We calculated health utility scores using the EQ-5D-
3L responses and the UK [8] and Canadian preference
weights [9]. We did not compute health utility scores for
participants who failed to answer one or more of the
EQ-5D-3L questions. Participants with missing health
utility scores were excluded from statistical analyses
involving these scores.
Statistical analysis
Socio-demographic characteristics were summarized
using medians and interquartile ranges for continuous
variables, and frequencies for categorical variables. We
used 1000 bootstrap samples to calculate bias corrected
and adjusted 95 % confidence intervals (CIs) for all
median health utility scores. We assessed the statistical
significance of the median differences between the UK
and Canadian health utility scores using the Wilcoxon
signed rank sum test. Hodges-Lehmann’s methods for
paired groups were employed to calculate the median
differences and the 95 % confidence intervals for the me-
dian differences.
The overall agreement between the UK and Canadian
health utility scores was assessed with the intraclass cor-
relation coefficient (ICC), specifically the ICC(3,1) [16].
Bland-Altman plots [17] were created to graphically de-
pict the difference in each participant’s health utility
score (the score based on UK weights subtracted by the
score based on Canadian weights).
We tested the association between socio-demographic
factors (i.e., age, gender, education level, occupation, and
annual household income) and each set of health utility
scores using a generalized linear model (GLM) with a
gamma distribution and bootstrap 95 % CIs for the regres-
sion coefficients. This type of GLM was shown to opti-
mally fit the data compared to a generalized additive
model, quantile regression by means of residual plots, and
analysis of variance. We employed the Akaike Information
Criterion (AIC) to choose the optimal model from among
these different approaches. Based on the literature [18],
we considered a change in health utility score of 0.074 to
be a minimum clinically important difference (MCID).
Most analyses were carried out using R v3.2.0 (R
Foundation for Statistical Computing, Vienna, Austria).
To calculate the ICC (3,1), we used a two-way mixed-
effects analysis of variance model and absolute agreement
in SPSS v19 (IBM Corp., Armonk, NY).
Results
A total of 216 persons with AD and their primary informal
caregivers were included in the study (Table 1). The
median age was 80 years for persons with AD and 69 years
for caregivers. One-hundred five persons with AD
(48.6 %) were female and the majority (n = 143, 66.2 %) of
caregivers were female. Most persons with AD (n = 112,
51.9 %) did not exceed a high school education and all
except one were retired. Most caregivers (n = 147, 68.1 %)
had a post-secondary education and 140 (64.8 %) were
retired. Most (n = 175, 81.0 %) persons with AD were
diagnosed with mild AD and the rest were diagnosed with
moderate AD. Over 50 % of participants in both groups
reported no problems in all five EQ-5D-3 L dimensions
(Table 2).
For persons with AD and caregivers, the distributions
of health utility scores derived from the UK and
Canadian preference weights were left-skewed (Figs. 1
and 2). Half of the persons with AD had health utility
scores above 0.85 (UK weights) or 0.84 (Canadian
weights). Similarly, half of the caregivers had scores
above 0.80 (UK weights) or 0.83 (Canadian weights). We
could not compute health utility scores for three persons
with AD because they did not answer all of the ques-
tions on the EQ-5D-3L.
The difference between the two sets of health utility
scores was not statistically significant in persons with
AD (p = 0.63) (Table 3). However, the difference was




(n = 216) (n = 216)
Age (years) 80 (78,81) 69 (59,77)
Gender Female 105 (48.6) 143 (66.2)
Educationb High school or less 112 (51.9) 69 (31.9)
College 35 (16.2) 50 (23.1)
University 43 (20.0) 69 (31.9)
Post-graduate 24 (11.1) 28 (13.0)
Missing 2 (0.9) 0
Occupation Retired 194 (89.8) 140 (64.8)
Working 1 (0.5) 60 (27.8)
Otherc 21 (9.7) 16 (7.4)
Annual household incomed <$40,000 64 (29.6) 59 (27.3)
$40,000-$80,000 42 (19.4) 78 (36.1)
>$80,000 22 (10.2) 63 (29.2)
No answer/Refused 88 (40.7) 16 (7.4)
Visual analogue scale
(0 – 100)
80 (70,90) 80 (70,90)
Note. AD Alzheimer’s Disease
aMedian (25th,75th percentiles) for age and visual analogue scale; n (%) for all
other variables
bCollege: some college or completed college; university: some univeristy or
completed university; post-graduate: some university at Masters or Doctorate
level or completed a Masters or Doctorate
cHomemaker, student, or unemployed
dCanadian dollars
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statistically significant in the caregivers (median differ-
ence: 0.009 [95 % CI: 0.007, 0.013]), with the median
score being higher (higher meaning better health) when
calculated with the Canadian versus UK preference
weights. Within each set of preference weights (UK
versus UK, Canadian versus Canadian), the difference in
health utility scores between persons with AD and care-
givers was not statistically significant.
The Canadian utilities were higher than the UK util-
ities in the caregiver group when the caregivers were
stratified according to the disease severity (mild, moder-
ate) of the persons under their care (Table 4). Median
differences were 0.009 (95 % CI: 0.007, 0.013) in the mild
subgroup and 0.013 (95 % CI: 0.007, 0.028) in the
moderate subgroup. For persons with AD, the UK and
Canadian health utility scores did not differ significantly.
Table 2 EQ-5D-3L responses
Persons with AD – n (%) Caregivers – n (%)




Age < 65 Years
(n = 76)
Age ≥ 65 Years
(n = 140)
Mobility No problems 12 (92) 140 (69) 69 (91) 81 (58)
Some problems 1 (8) 62 (31) 7 (9) 59 (42)
Confined to bed 0 (0) 1 (<1) 0 (0) 0 (0)
Self-care No problems 12 (92) 181 (89) 76 (100) 134 (96)
Some problems 1 (8) 21 (10) 0 (0) 6 (4)
Unable to wash or dress 0 (0) 0 (0) 0 (0) 0 (0)
Missing 0 (0) 1 (<1) 0 (0) 0 (0)
Usual activities No problems 8 (62) 143 (70) 68 (90) 88 (63)
Some problems 5 (38) 57 (28) 8 (10) 50 (36)
Unable to wash or dress 0 (0) 2 (1) 0 (0) 2 (1)
Missing 0 (0) 1 (< 1) 0 (0) 0 (0)
Pain/discomfort No 12 (92) 133 (66) 51 (67) 60 (43)
Moderate 1 (8) 69 (34) 24 (32) 76 (54)
Extreme 0 (0) 1 (< 1) 1 (1) 4 (3)
Anxiety/depression No 8 (62) 151 (74) 52 (68) 92 (66)
Moderate 5 (13) 48 (24) 23 (30) 46 (32)
Extreme 0 (0) 3 (2) 1 (1) 2 (1)
Missing 0 (0) 1 (< 1) 0 (0) 0 (0)
Note. AD Alzheimer’s Disease
Fig. 1 Distribution of health utility scores for persons with Alzheimer’s disease. AD = Alzheimer’s disease; UK = United Kingdom
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The overall agreement between health utility scores
using UK and Canadian preference weights was high.
The ICC (3,1)s were 0.94 (95 % CI: 0.92, 0.95) for per-
sons with AD and 0.92 (95 % CI: 0.88, 0.94) for care-
givers. According to the Bland-Altman plots, 95 % of the
>individual differences in health utility scores (UK – Can-
adian) fell within a range of -0.12 to 0.12 for persons with
AD and within -0.16 to 0.12 for caregivers (Fig. 3). For
persons with AD, only 15 (7 %) of the individual differ-
ences in score exceeded the MCID of 0.074; for caregivers,
the number was also 15 (9 %).
With respect to socio-demographic characteristics,
only some education categories were associated with the
two sets of health utility scores (Table 5). The scores for
persons with AD who had a post-graduate education
were an average of 0.1 points lower (UK weights) or
0.059 points lower (Canadian weights) than the scores
for persons who had a high school or less education.
The scores for caregivers with a post-graduate education
were an average of 0.116 points lower (UK weights) or
0.04 points lower (Canadian weights) than the scores for
caregivers with a high school or less education. Care-
givers with a university education also had average
scores that were 0.131 points lower than caregivers
with a high school or less education. No other socio-
demographic variables were statistically significantly
associated with either set of health utility scores. Three of
the statistically significant associations exceeded the
MCID of 0.074.
Discussion
In this study of persons with AD and their primary infor-
mal caregivers, health utility scores derived from UK and
Canadian preference weights exhibited slight differences
from one another. Based on the MCID, these differences
were not large enough to be considered clinically import-
ant. We could not find other studies that compared health
utility scores calculated with UK and Canadian preference
weights.
Evidence suggests health utility scores can be
similar for people across countries with comparable
socio-demographic characteristics (i.e., UK, Holland, and
Germany [19] Spain and Germany [20]). Given the socio-
demographic parallels between the UK and Canadian
populations, the samples used to derive the UK and
Fig. 2 Distribution of health utility scores for caregivers. UK = United Kingdom
Table 3 Median EQ-5D-3L health utility scores
UK-based preference
weights (95 % CI)
Canadian-based preference
weights (95 % CI)
Persons with AD 0.85 (0.81, 0.88)a,b 0.84 (0.83, 0.84)a,c
Caregivers 0.80 (0.80, 0.85) b,d 0.83 (0.83, 0.83) c,d
Note. AD Alzheimer’s disease, CI confidence interval, UK United Kingdom,
Health utility scores were not calculated for three persons with AD who did
not answer all of the EQ-5D-3L questions
ap = 0.63 for median difference in persons with AD (UK versus
Canadian weights)
bp = 0.06 for median difference in persons with AD versus caregivers
(UK weights)
cp = 0.35 for median difference in persons with AD versus caregivers
(Canadian weights)
dp < 0.0001 for median difference in caregivers (UK versus Canadian weights)
Table 4 Median EQ-5D-3L health utility scores stratified by disease
severity
Severity UK-based preference
weights (95 % CI)
Canadian-based
preference
weights (95 % CI)
Persons
with AD
Mild (n = 173) 0.85 (0.85,0.88)a 0.84 (0.84,0.84)a
Moderate (n = 40) 0.81 (0.73,0.88)b 0.82 (0.74,0.84)b
Caregivers Mild (n = 175) 0.81 (0.80,0.85)c 0.83 (0.83,0.83)c
Moderate (n = 41) 0.80 (0.80,0.80)d 0.83 (0.80,0.84)d
Note. AD Alzheimer’s disease, CI confidence interval, UK United Kingdom,
Health utility scores were not calculated for three persons with AD who did
not answer all of the EQ-5D-3L questions
ap = 0.59 for median difference in persons with AD within mild stratum
bp = 0.98 for median difference in persons with AD within moderate stratum
cp < 0.0001 for median difference in caregivers within mild stratum
dp = 0.009 for median difference in caregivers within moderate stratum
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Canadian preference weights [8, 9] may have simply
valued their health states similarly to one another. Thus,
the health utility scores derived from each set of prefer-
ence weights in this study did not differ appreciably from
one another.
On the other hand, not every population with similar
socio-demographic characteristics will place comparable
value on the same health states. Representative samples
of the United States (US) and UK populations valued 42
EQ-5D-3L health states and the adjusted mean differ-
ence in health utility scores was 0.10 points higher in
the US population [21]. An earlier study involving the
same sample as in the present study compared health
utilities calculated with US and Canadian preference
weights [12]. This comparison showed that Americans
and Canadians agreed on the types of health states that
should be considered ‘good’ or ‘bad’, but Canadians
tended to place a lower value than Americans on
most of these health states. When calculated with
Canadian versus American preference weights, the
mean health utility score was 0.06 points lower (95 %
CI: -0.07, -0.06) in persons with AD and 0.05 points
lower (95 % CI: -0.06, -0.04) in caregivers.
The findings reported in the literature raise a caution
for researchers who wish to calculate health utility
scores for study samples drawn from populations for
which preference weights do not exist. The default prac-
tice in these situations has been to use preference
weights derived from similar populations, but this ap-
proach could lead to over- or under-estimates of health
utility scores. In the absence of preference weights for
the population of interest, one can never be certain
whether another population’s weights will provide un-
biased results.
The caution about transferability of weights also
applies to the EQ-5D-5L, which measures the same
five health dimensions as the EQ-5D-3L, but expands
the number of response options from three to five
[22]. Recent work involving the EQ-5D-5L suggests
that one set of preference weights may not capture
inter-regional differences in a single country’s popula-
tion if the population is spread over a large geo-
graphic area [23].
In our study, only a small number of socio-demographic
characteristics affected the UK and Canadian health utility
scores. Perhaps disease-specific factors, rather than socio-
demographic characteristics, could better explain the
scores in AD samples. In persons with AD, some studies
have shown that health utility scores are affected by
levels of depression and functional ability [24, 25].
Other work has suggested that a more complex series
of socio-demographic and disease factors combine to
modify the relation between disease severity and
health utility scores [26]. For caregivers, health utility
scores may be influenced by the extent to which pa-
tients are dependent on care, the perceived burden of
being a caregiver, and the time involved in providing
care [27, 28]. Researchers should consider these add-
itional variables when they design studies to explain
health utility scores in AD samples.
Fig. 3 Bland-Altman plots. AD = Alzheimer’s disease; UK = United Kingdom
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Our study found that most caregivers’ health utility
scores were lower than the scores of persons with
AD. The burden of caring for a person with AD may
adversely affect a caregivers’ HRQoL [29]. Meanwhile,
the effects of cognitive impairment might prevent
persons with AD from perceiving the full impact of
disease on their lives, therefore leading to high ratings
of HRQoL [30, 31].
Few studies could be found that assessed the HRQoL
of AD caregivers. One study conducted on the Canary
Islands reported that the frequency of having at least
some problems on each EQ-5D-3L dimension was
greater in 237 AD caregivers compared to the islands’
general population [27]. However, the authors did not
convert EQ-5D-3L responses into health utility scores.
The caregiver utility scores in our study were somewhat
lower than the scores reported in two studies (i.e., 0.87
[32], 0.88 [33]) of general adult populations in Canada,
and about the same as the scores reported in a third
Canadian study (i.e., 0.85 female, 0.81 male) [34].
Readers should take certain issues into account when
interpreting the results of this study. The participants
were recruited from geriatric or memory clinics, so they
are unlikely to be representative of the average person
with AD or the average caregiver. The participants with
AD may be a healthier subset of all patients and the
caregivers may be more informed about AD.
Conclusion
Health utility scores exhibited some small yet clinically
unimportant differences when calculated with UK versus
Canadian preference weights in a sample of persons with
AD and their caregivers. The UK and Canadian popula-
tions used to obtain the preference weights valued health
states similarly to one another.
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